

My name: \_\_\_\_\_

My contact number: \_\_\_\_\_

Emergency contact: \_\_\_\_\_

Emergency contact  
number: \_\_\_\_\_

Name of Oncologist/  
Oncology Nurse: \_\_\_\_\_

Contact number: \_\_\_\_\_

Name of my Hospital: \_\_\_\_\_

My Hospital contact  
number: \_\_\_\_\_

PADCEV start date: \_\_\_\_\_

**PADCEV**<sup>TM</sup>  
(enfortumab vedotin)

## PATIENT CARD



v.3 : This Patient Card format  
and content was approved  
according to the guidelines of the  
ministry of health on Sep2025

VV-PVG-007366

- Carry this card with you **at all times**, especially when you travel or when you see another doctor.
- Please ensure you show this card to any doctor, pharmacist or nurse for any medical treatment or at any visits to the hospital or clinic.
- Please contact your doctor **immediately**, if you develop any side effects, in particular those listed on this card.

## IMPORTANT SAFETY INFORMATION FOR PATIENTS

**Padcev may cause serious side effects, including severe skin reactions (Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and other severe rashes such as symmetrical drug related intertriginous and flexural exanthea).**

Talk to your doctor, pharmacist or nurse **immediately** if you have any of the following symptoms:

- Target lesions (skin reactions that look like rings)
- rash or itching that continues to get worse or comes back after treatment,
- skin blistering or peeling,
- painful sores or ulcers in mouth, nose, throat, or genital area,
- fever or flu like symptoms or swollen lymph nodes.

These may be signs of a severe skin reaction that can happen while receiving this medicine, particularly during the first few weeks of treatment. If it occurs, your doctor will monitor you and may give you medicine to treat

your skin condition. She or he may pause or stop treatment if your skin reaction worsens. If you have any further questions about your treatment, please contact your doctor.

## IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient is being treated with Padcev (enfortumab vedotin), which can cause severe skin reactions, including SJS and TEN (predominantly during the first cycle of treatment).
- Symptoms include rash or itching that continues to get worse or comes back after treatment, skin blistering or

peeling, painful sores or ulcers in mouth, nose, throat, or genital area, fever or flu-like symptoms or swollen lymph nodes.

- Fever or flu-like symptoms may be the first sign of a skin reaction. Patients should be monitored starting with the first cycle and throughout treatment for skin reactions. Topical corticosteroids/antihistamines can be considered for mild to moderate skin reactions.
- If SJS or TEN is suspected or if bullous lesions occur,

**immediately** withhold treatment and refer for specialised care; histologic confirmation is critical to early recognition, as diagnosis and intervention can improve prognosis.

- If SJS or TEN, Grade 4 or recurrent Grade 3 skin reactions occur, permanently discontinue treatment.
- For persistent or recurrent Grade 2 skin reactions consider withholding until Grade  $\leq 1$ , then resume treatment at the same dose level or dose reduce by one dose level.

- For Grade 3 skin reactions withhold until Grade  $\leq 1$ , then resume treatment at the same dose level or dose reduce by one dose level.

**Please contact the patient's Oncologist for more information and consultation.**

Additional information for the patient is also available in the PADCEV Patient Booklet that should be shared with you via your doctor and also available at: <https://israeldrugs.health.gov.il/#!/medDetails/167%2037%2036604%2000>

Adverse events reporting: Adverse events can be reported directly to the Ministry of Health using the adverse events digital form which available on the home page of the Ministry of Health website: [www.health.gov.il](http://www.health.gov.il) or by this link: <https://sideeffects.health.gov.il/>

Adverse events can also be reported to Astellas Pharma International B.V using the following email: [Pharmacovigilance.IL@astellas.com](mailto:Pharmacovigilance.IL@astellas.com)